Eleven U.S. stocks with buybacks amid market pessimism

The screen highlights U.S. companies with market caps above US$5B that combine FCF yield above 5%, sales growth above 10%, EV/EBITDA below 10x, and aggressive buybacks, suggesting undervalued fundamentals despite weak share performance. The Trade Desk stands out with a 61.5% one-year decline but 16.2% sales growth and a 148.3% BBY/FCFY ratio; Universal Health Services and EPAM also screen well on growth and valuation. The article is primarily a contrarian stock-selection piece rather than a company-specific catalyst, so direct market impact is limited.

Analysis

The common thread across these names is not just cheapness, but management signaling. Aggressive repurchases after a sharp drawdown usually matter most when the business still has operating leverage left to defend — that can create a reflexive setup where lower share counts support EPS while sentiment remains anchored to old peak multiples. The second-order effect is that these companies can re-rate faster than the broader market expects once buybacks absorb incremental supply and buy-side positioning is still underweight.

TTD is the cleanest contrarian expression, but also the most fragile. The market is effectively pricing a prolonged competitive or demand reset, so the key question is whether repurchases are merely offsetting employee dilution or are truly absorbing meaningful float; if the latter, the marginal seller has already been exhausted and a sharp squeeze is possible over the next 3-6 months. Still, ad-tech is prone to narrative whiplash, so the downside case is that buybacks are a confidence signal rather than proof of durability if revenue decelerates again.

UHS screens as the most defensive value compounder: low multiple, positive momentum, and capital return support create a better margin of safety than the other two names. The hidden risk is political/regulatory rather than competitive — hospital reimbursement or labor cost pressure can lag the headline fundamentals by several quarters, so the stock can keep working until a policy shock resets margins. EPAM is the highest-quality cyclical recovery, but it is more dependent on IT spend stabilization than on internal capital allocation; if enterprise software budgets re-accelerate, multiple expansion can happen quickly, but if macro stays soft, the buyback just slows the bleed.

Consensus is likely missing how much of the downside has already been expressed in price versus how much of the remaining risk is now business-specific. That makes these names more attractive as a basket than individually: the market is punishing them for sentiment, while management is effectively underwriting that the cash-generation profile is intact. The trade-off is timing — these are 3-12 month trades, not next-week catalysts, and the best entry is on any post-earnings weakness that confirms buybacks remain active.

Key Decisions for Investors

• Go long a basket of TTD/UHS/EPAM on post-earnings weakness over the next 1-2 quarters; target 15-25% upside on a 6-12 month horizon if buyback activity persists and fundamentals do not deteriorate.
• Buy TTD as the highest-beta contrarian recovery trade, but size smaller; use a 3-6 month window and pair with a short in a more expensive ad-tech/marketing software name if available, because the upside is fastest if sentiment snaps back.
• Prefer UHS as the core long for a lower-volatility expression; hold 6-12 months and expect mid-single-digit downside protection from capital returns, with rerating potential if healthcare reimbursement headlines remain benign.
• Use EPAM as a cyclical quality trade only if enterprise IT spending data stabilizes; enter on any analyst-driven downdraft, with a 6-9 month target tied to margin normalization and multiple expansion rather than pure earnings growth.
• Avoid naked shorting these names into buyback-heavy periods; if expressing skepticism, hedge via a sector basket or market hedge instead, since repurchases can create a sharp squeeze when float supply is thin.